Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China

BACKGROUND: Though bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) have been regulatory approved and included in the National Reimbursement Drug List in China, due to the affordability concern, generic version of efavirenz + lamivudine + tenofovir (EFV + 3TC + TDF) is still recommended as the firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Cao, Wei, Tang, Ning, Wang, Fang, Zheng, Gang, Xiao, Xingzhi, Wang, Guoqiang, Zhou, Min, Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258991/
https://www.ncbi.nlm.nih.gov/pubmed/37308847
http://dx.doi.org/10.1186/s12879-023-08359-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258991/
https://www.ncbi.nlm.nih.gov/pubmed/37308847
http://dx.doi.org/10.1186/s12879-023-08359-w

Ejemplares similares